Table 2.
Treatment-related characteristics of HSCT survivors (BMTSS) and conventionally treated cancer survivors (CCSS)
| Treatment-related variables | BMTSS (N = 145) | Conventionally treated, CCSS (N = 7207) | P |
|---|---|---|---|
| Year of diagnosis | < .01 | ||
| 1970-1975 | 3 (2.1) | 1745 (24.2) | |
| 1976-1981 | 21 (14.5) | 2636 (36.6) | |
| 1982-1986 | 24 (16.6) | 2826 (39.2) | |
| 1987-1991 | 49 (33.8) | N/A | |
| 1992-1997 | 48 (33.1) | N/A | |
| Age at diagnosis, y | < .01 | ||
| Mean (± SD) | 10.9 ± 6.9 | 8.9 ± 5.7 | |
| Range | 0.1-20.9 | 0.1-20.9 | |
| Diagnosis | < .01 | ||
| Acute myeloid leukemia | 73 (50.3) | 267 (3.7) | |
| Acute lymphoblastic leukemia | 51 (35.2) | 4017 (55.7) | |
| Hodgkin lymphoma | 11 (7.6) | 1879 (26.1) | |
| Non-Hodgkin lymphoma | 10 (6.9) | 1044 (14.5) | |
| Time from diagnosis, y | < .01 | ||
| Mean (± SD) | 12.9 ± 5.6 | 16.2 ± 4.9 | |
| Range | 5.1-26.1 | 6.4-31.1 | |
| Chemotherapy | |||
| Anthracycline, mg/m2 | < .01 | ||
| None | 12 (8.3) | 3689 (61.0) | |
| 1-249 | 73 (50.3) | 1167 (19.3) | |
| ≥ 250 | 60 (41.4) | 1194 (19.7) | |
| Alkylating agent | < .01 | ||
| None | 99 (68.3) | 2467 (44.5) | |
| Alkylating agent score 1-2 | 38 (26.2) | 2322 (41.9) | |
| Alkylating agent score ≥ 3 | 8 (5.5) | 752 (13.6) | |
| Epidophyllotoxins | < .01 | ||
| Any | 65 (44.8) | 497 (8.0) | |
| Platinum agents | < .01 | ||
| Any | 8 (5.5) | 19 (0.3) | |
| Radiation | |||
| Brain | 25 (17.2) | 2550 (35.4) | < .01 |
| Chest | 8 (5.5) | 1665 (23.1) | < .01 |
| HSCT-related | |||
| Autologous HSCT | 40 (27.6) | N/A | |
| Allogeneic-related | 85 (58.6) | N/A | |
| Allogeneic-unrelated | 20 (13.8) | N/A | |
| Disease status at HSCT | |||
| First complete remission (CR1) | 85 (58.6) | N/A | |
| ≥ CR1 | 50 (34.5) | N/A | |
| Conditioning | |||
| Chemotherapy | 34 (23.4) | N/A | |
| Chemotherapy + TBI | 111 (76.6) | N/A | |
| Chronic GVHD* | |||
| No | 71 (67.6) | N/A | |
| Resolved | 20 (19.0) | N/A | |
| Active | 14 (13.3) | N/A |
Percentages are determined from the total number of participants who provided data for each variable, rather than on total number in each cohort.
BMTSS indicates Bone Marrow Transplant Survivor Study; CCSS, Childhood Cancer Survivor Study; N/A, not applicable; and TBI, total body irradiation.
*
Limited to allogeneic HSCT (N = 105).